At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Furmonertinib 160 mg, Q.D.drug
Likely dose
Furmonertinib 160 mg, Q.D.from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial（iFORCE）
In Brief
A Phase 2 clinical trial evaluating Furmonertinib 160 mg, Q.D. for Furmonertinib and 3 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFurmonertinib, EGFR-mutation, NSCLC, Brain Metastases
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartJul 2022
First PostedJul 2022
Primary CompletionDec 2025
TodayJul 2026
First PostedJul 19, 2022
Enrollment StartJul 11, 2022
Primary CompletionDec 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.0 years ago
Interventions
Furmonertinib 160 mg, Q.D.drug
Furmonertinib 160 mg orally once daily in previously treated groups